Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 123   

Articles published

4502 5,983.00 -14.00 (-0.23%)
price chart
Orexigen Therapeutics, Inc. (NASDAQ:OREX) and Takeda Pharmaceutical Co ...
Dallas, Texas 06/30/2015 (Financialstrend) - Orexigen Therapeutics, Inc. (NASDAQ:OREX) has gone to court to block a generic version of its diet pill Contrave.
Corrections in Focus - Orexigen Therapeutics (OREX), FXCM (FXCM), Youku ...  Techsonian (press release)
Takeda Pharmaceutical Co Ltd (ADR) Plans To Offer $2.2 Billion To Settle Actos ...
Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) has, as per anonymous sources, expressed its willingness to put down over $2.2 billion in an attempt to settle claims that the company deliberately withheld information about the risk of cancer from ...
Drugmaker Takeda may settle Actos suits for $2.2 billion  The Japan Times
Japan's Takeda Pharmaceutical offers $2.2 billion to settle US drug lawsuits  Economic Times
Takeda Announces Appointment of New President of U.S. Business Unit
DEERFIELD, Ill., April 13, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.
Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib.
First patient enrolled in Phase 3 study of ixazomib as maintenance therapy ...  European Pharmaceutical Review
Moody's: Takeda's rating not immediately impacted by ACTOS settlement ...
Tokyo, May 01, 2015 -- Moody's Japan K.K. says that the A1 issuer and senior unsecured debt ratings as well as (P)A1 shelf registration of Takeda Pharmaceutical Company Limited ("Takeda") will not be immediately impacted following its 28 April 2015 (U ...
Takeda Pharma drops on $2.7bn charge to settle Actos lawsuits  International Business Times UK
Actos lawsuits settlement  Lexology (registration)
Immunogen (IMGN), Takeda Enter Licensing Agreement Covering ADC ...
Takeda Pharmaceutical Company Limited and ImmunoGen, Inc. (Nasdaq: IMGN) announced that Takeda has licensed exclusive rights to use ImmunoGen's ADC technology - including ImmunoGen's new DNA-acting IGN payload agents - to develop and ...
ICYMI: Pharmaceutical Stocks Are Moving Big On Monday  Benzinga
ImmunoGen, Inc. (NASDAQ:IMGN) announced a licensing agreement with ...  Inside Trade
Takeda Pharmaceutical to stay Japan-based while growing on global basis, new ...
The inauguration in June of Christophe Weber as president of Takeda Pharmaceutical Co. invited opposition from a group of its former executives and members of its founding family, but the Frenchman says Takeda will remain “Japanese-based” under his ...
Related articles »  
Sanford Consortium, Takeda Pharmaceutical Partner in $10-Million "Innovation ...
Newswise - The Sanford Consortium for Regenerative Medicine in La Jolla, California, and the Takeda Pharmaceutical Company Limited (Takeda) have agreed to establish a $10-million, five-year Innovation Alliance that would advance each organization's ...
Sanford Consortium, Takeda partner in $10M Innovation Alliance  San Diego Source (subscription)
Takeda Pharmaceutical Co Lowered to "Hold" at Zacks (TKPYY)
Zacks' analyst wrote, “Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs.
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
CLEVELAND & OSAKA, Japan, Sep 25, 2014 (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly ...
Related articles »